GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » Change In Inventory

Global Blood Therapeutics (Global Blood Therapeutics) Change In Inventory : $-16.1 Mil (TTM As of Jun. 2022)


View and export this data going back to 2015. Start your Free Trial

What is Global Blood Therapeutics Change In Inventory?

Global Blood Therapeutics's change in inventory for the quarter that ended in Jun. 2022 was $-3.4 Mil. It means Global Blood Therapeutics's inventory increased by $3.4 Mil from Mar. 2022 to Jun. 2022 .

Global Blood Therapeutics's change in inventory for the fiscal year that ended in Dec. 2021 was $-16.1 Mil. It means Global Blood Therapeutics's inventory increased by $16.1 Mil from Dec. 2020 to Dec. 2021 .

Global Blood Therapeutics's Total Inventories for the quarter that ended in Jun. 2022 was $65.8 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Global Blood Therapeutics's Days Inventory for the quarter that ended in Jun. 2022 was 4,125.95.

Inventory Turnover measures how fast the company turns over its inventory within a year. Global Blood Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2022 was 0.02.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Global Blood Therapeutics's Inventory-to-Revenue for the quarter that ended in Jun. 2022 was 0.89.

Global Blood Therapeutics Change In Inventory Historical Data

The historical data trend for Global Blood Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Global Blood Therapeutics Change In Inventory Chart

Global Blood Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Change In Inventory
Get a 7-Day Free Trial Premium Member Only - - -1.28 -36.78 -16.15

Global Blood Therapeutics Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.27 -3.06 -6.25 -3.39 -3.42

Global Blood Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Global Blood Therapeutics  (NAS:GBT) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Global Blood Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=63.89/1.413*365 / 4
=4,125.95

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Global Blood Therapeutics's Inventory Turnover for the quarter that ended in Jun. 2022 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=1.413 / 63.89
=0.02

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Global Blood Therapeutics's Inventory to Revenue for the quarter that ended in Jun. 2022 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=63.89 / 71.55
=0.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Global Blood Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Global Blood Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Global Blood Therapeutics (Global Blood Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Global Blood Therapeutics Inc (NAS:GBT) » Definitions » Change In Inventory
Comparable Companies
BCRX AUPH TPTX CCXI SWTX RLAY PCVX LGND SAGE KRYS OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
181 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Website
https://www.gbt.com
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Executives
Jeffrey S Farrow officer: Chief Financial Officer TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Nazila Habibizad officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD SOUTH SAN FRANCISCO CA 94080
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Philip A. Pizzo director ONE COMMERCE STREET, SUITE 2550, MEMPHIS TN 38103
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Carrie Krehlik officer: Chief Human Resources Officer 6015 COLTON BLVD, OAKLAND CA 94611
Eric Fink officer: Chief Human Resources Officer C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Kim Smith-whitley officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Alexis A. Thompson director C/O GLOBAL BLOOD THERAPEUTICS, INC. 181 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Brian Edwin Cathers officer: Chief Scientific Officer C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080
Lesley Ann Calhoun officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Mark L Perry director 176 WEST BLITHEDALE AVE, MILL VALLEY CA 94941
Ted W Love director, officer: See Remarks C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Tricia Borga Suvari officer: Chief Legal Officer 3172 PORTER DRIVE PALO ALTO CA 94034
Brown Willie L. Jr. director C/O GLOBAL BLOOD THERAPEUTICS, INC. 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO CA 94080